Figure 5.

Immunofluorescence analysis of Caki-1 tumour sections stained with EMT markers. Representative pictures of vimentin and E-cadherin staining for each group of treatment (A).Vimentin (B) and E-cadherin (C) expression were quantified by Image J software for mice with tumours treated with vehicle control (C), 60 mg kg⁻¹ per day sunitinib (S), 10 mg kg⁻¹ per day everolimus (E), sequential combination of 60 mg kg⁻¹ per day sunitinib, and 10 mg kg⁻¹ per day everolimus as a single group (S/E) composed with treatment of alternate drugs administration every week (1W), every 2 weeks (2W), and every 3 weeks (3W). Ratios of vimentin expression to E-cadherin expression were calculated in each treatment group (D). For each treatment group a double bar graph represent in one hand the mice with quick progressive disease (PG) and in the other hand the mice with sustained (ST) tumour control. Values represent the means±s.e.m. of at least five quantifications per animal with five animals per group, ***P<0.005, **P<0.01, *P<0.05, NS=non significant, ^#symbol stands for no calculable P-values due to the small sample number.